NRX Pharmaceuticals Warrant
NRXPW
NRXPW was delisted on the 22nd of May, 2026.
4 hedge funds and large institutions have $24K invested in NRX Pharmaceuticals Warrant in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
78% less capital invested
Capital invested by funds: $110K → $24K (-$86K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$295 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$28.7K |
| 2 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$13.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
YCM
1
Yakira Capital Management
Westport,
Connecticut
| $15K | -$13.1K | -8,919 | -34% |
|
|
2
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $9K | -$28.7K | -19,450 | -66% |
|
|
3
UBS Group
Zurich,
Switzerland
| – | -$8K | -4,358 | Closed |
|
|
4
Bank of America
Charlotte,
North Carolina
| – | +$295 | +200 | New |
|
NRXPW Hedge Fund Activity: Q1 2022 in Review
4 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q1 2022, worth a combined $24K — down 78% from $110K a quarter earlier.
Fund positioning in NRXPW was balanced in Q1 2022: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 2 trimmed.
The largest buyer was Bank of America, opening a new position worth an estimated $295. The largest seller was Cambridge Investment Research Advisors, cutting an estimated $28.7K.
- 4 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $24K of NRX Pharmaceuticals Warrant stock for Q1 2022, down 78% quarter-over-quarter.
- 1 fund opened new NRX Pharmaceuticals Warrant positions in Q1 2022 and 1 closed out, a net change of 0 holders.
- The largest NRX Pharmaceuticals Warrant buyer in Q1 2022 was Bank of America, an estimated $295 added.
- The largest NRX Pharmaceuticals Warrant seller in Q1 2022 was Cambridge Investment Research Advisors, an estimated $28.7K sold.
Based on aggregated 13F filings for Q1 2022.